GI CANCERS
Latest News
Latest Videos
More News
Non-Hodgkin Lymphoma
Daniel Catenacci, MD, discusses how he makes decisions with immunotherapeutic agents for the treatment of patients with gastroesophageal junction cancer. He says he bases his sequencing decisions on a number of factors.
Scott Kopetz, MD, PhD, explains how prognoses for patients with colorectal cancer differ based on whether their cancer is left-sided or right-sided and discusses how knowledge of these differences have led to the development of more agents to treat both groups of patients.
The combination of onvansertib, a third-generation adenosine triphosphate inhibitor, with FOLFIRI and bevacizumab achieved positive responses in patients with metastatic colorectal cancer in the second-line setting, according to the results of a phase Ib/II reported in a press release from Trovagene, Inc.<br />
The FDA has approved a supplemental New Drug Application for a single dose of aprepitant injectable emulsion for intravenous use in patients receiving moderately emetogenic chemotherapy. The approval expands the dose for aprepitant to include a 130 mg single-dose regimen for the prevention of acute and delayed chemotherapy-induced nausea and vomiting.<br />
Pamela L. Kunz, MD, discusses the most recent FDA approval of Lutathera (lutetium [Lu 177] dotatate) for the treatment of patients with gastroenteropancreatic NETs (GEP-NETs), including foregut, midgut, and hindgut tumors.
TAS-102 improved overall survival in patients with metastatic gastric/gastroesophageal junction cancer, regardless of prior gastrectomy, according to a preplanned subgroup analysis from the phase III TAGS trial published in <em>JAMA Oncology</em>.<br />
Treatment targeting molecular pathways such as <em>BRAF, </em>HER2<em>,</em> and <em>RAS</em> has typically been reserved for later lines of therapy for patients with metastatic colorectal cancer. Benjamin A. Weinberg, MD, said that agents targeting these pathways are not yet ready for the upfront setting, but data from ongoing trials suggest that these agents may eventually have a role to play in first- and second-line treatment.
In an interview with <em>Targeted Oncology</em>, Daniel Catenacci, MD, discussed the clinical trials supporting immunotherapeutic options for patients with GEJ cancer. He also highlighted how physicians can sequence these agents appropriately in their patients.
Immunotherapeutic agents have grown in popularity for treating mismatch repair–deficient metastatic colorectal cancer, becoming the standard of care in the second line, Howard Hochster, MD, told an audience at the 2019 Gastrointestinal Oncology Conference. Furthermore, ongoing clinical trials suggest that these agents may play a larger role in treating CRC going forward.
David H. Ilson, MD, PhD, discusses the current role of pembrolizumab in patients with gastric cancer or gastroesophageal junction adenocarcinoma based on the results from the KEYNOTE-062 trial.
In a presentation at the 2019 ESMO Congress on a case series of 7 pretreated patients with <em>NRG1</em>-positive tumors, Stephen Liu, MD, and colleagues discussed the efficacy of afatinib and explained that afatinib may be a potential treatment option for <em>NRG1</em>-positive tumors across multiple cancer types.
In an interview with <em>Targeted Oncology</em>, Michael A. Choti, MD, MBA discussed the treatment landscape for patients with pancreatic cancer, as well as how the role of neoadjuvant chemotherapy in this space is changing. He highlights advantages of neoadjuvant strategies, and also some other treatment options for patients with pancreatic cancer.
The FOLFIRINOX regimen remains the treatment of choice for patients with pancreatic cancer even as clinical trials exploring potential therapies, including CD40 and CPI-613, offer the possibility of new options for a notoriously difficult-to-treat disease, Davendra P.S. Sohal, MD, MPH, told an audience at the 2019 Gastrointestinal Oncology Conference.
A pivotal multicenter, open-label, randomized phase III trial has been initiated to evaluate the efficacy and safety of the novel mitochondrial inhibitor, devimistat in combination with a modified FOLFIRNOX regimen for the first-line treatment of patients with metastatic pancreatic cancer, according to a press release from Rafael Pharmaceuticals.
Following the 2019 ESMO Congress, experts across various fields highlighted some next steps and how these treatment options will improve the treatment landscape for patients with ovarian, lung, breast, GI, or GU cancers. Overall, the abstracts presented at this year’s meeting will change the treatment paradigm in a number of patient populations.
Marcelo C. Pasquini, MD, discusses the rationale for analyzing real-world data for the use of tisagenlecleucel, a chimeric antigen receptor T-cell therapy, as a treatment for patients with acute lymphoblastic leukemia and diffuse large B-cell lymphoma. This CD19 CAR T cell was approved 2 years ago for use in both ALL and DLBCL.
The addition of direct oral oral anticoagulants for the management of venous thromboembolism in patients with cancer is the latest change to previous guidelines issued by the American Society of Clinical Oncology.
In an interview with <em>Targeted Oncology</em>, Gregory Gores, MD explained the role of molecular therapy and the use of genetic testing to guide treatment of iCCA.
Using a measure known as the growth modulation index, patients with TRK fusion–positive cancers who were treated with larotrectinib had a clinically meaningful improvement in progression-free survival compared with the time to progression on their prior treatment, an analysis of patients enrolled in 1 of 3 clinical trials has found.
During his presentation at the Cleveland Clinic Cholangiocarcinoma Symposium, Davendra P.S. Sohal, MD, MPH, reviewed promising novel therapies and those that recently gained indications for patients with cholangiocarcinoma.
The risk of progression or death was reduced by 63% with ivosidenib as treatment of pretreated patients with IDH1-mutant advanced cholangiocarcinoma compared with placebo, according to data from the phase III ClarIDHy study that was presented at the 2019 ESMO Congress.
Three clinical trials presented at the 2019 ESMO Congress show that the tropomyosin receptor kinase inhibitor larotrectinib continues to show anti-tumor activity, including long-lasting objective responses and low toxicity, according to results from an integrated analysis.
An objective response rate of 35.5% was seen with treatment with pemigatinib, a selective oral inhibitor of FGFR1, 2, and 3, in patients with previously treated, locally advanced or metastatic cholangiocarcinoma with an <em>FGFR2 </em>rearrangement or fusion, according to findings from the phase II FIGHT-202 clinical trial presented at ESMO 2019.